COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,731 Articles (22,502 medRxiv, 8,229 bioRxiv)

Most recent first Previous |  Page 48: Articles 471-480  | Next

SARS-CoV-2 nucleocapsid uniquely disrupts chromatin over pathophysiologically relevant gene promoters
Benoit, J. M., Dennis, J. H.
10.1101/2025.02.22.639619 — Posted: 2025-02-24
Flagellin in the human gut microbiome is a diet-adjustable adjuvant for vaccination
Huus, K. E., uHEAT Clinical Study Group, , Tan, Y. H., Abo, H., Keller, R., Atay, E., Vu, D. L., Dauser, S., Prokipchuk, A., Tyakht, A., Youngblut, N., Chassaing, B., Kang, S.-M., Parsonnet, J., Kremsner, P. G., Maier, L., Gewirtz, A. T., Esen, M., Ley, R. E.
10.1101/2025.02.21.639485 — Posted: 2025-02-24
Hematologic, Immunologic and Outcome Characteristics of Severe acute respiratory syndrome 2 (SARS-COV-2) among People Living with HIV in Eastern Uganda: A retrospective study
Otaala, T., Opito, R., Mugisha, K., Oryokot, B., Bakashaba, B., Esabu, M., Nbidde, S. N., Watmon, B., Etolu, W., Lubaale, M. Y., Olupot-Olupot, P.
10.1101/2025.02.22.25322708 — Posted: 2025-02-23
Food Insecurity and Food Practices among Child Care Workers During COVID-19
DYNIA, J., Koury, A. J., Bates, R. A.
10.1101/2025.02.20.25322598 — Posted: 2025-02-21
Estimates of underlying health biases in SARS-CoV-2 vaccination recipients: a nationwide study in previously-infected adults
Riedmann, U., Chalupka, A., Richter, L., Werber, D., Sprenger, M., Willeit, P., Rijksen, M., Lodron, J., Hoeg, T. B., Ioannidis, J., Pilz, S.
10.1101/2025.02.19.25322515 — Posted: 2025-02-21
EpiMolBio: A Novel User-Friendly Bioinformatic Program for Genetic Variability Analysis
Reinosa, R., Troyano-Hernaez, P., Valades-Alcaraz, A., Holguin, A.
10.1101/2025.02.21.639439 — Posted: 2025-02-21
Immunological and clinical markers of post-acute sequelae of COVID-19: Insights from mild and severe cases six months post-infection
Mouton, W., Djebali, S., Villard, M., Allatif, O., Chauvel, C., Benezech, s., Vanhems, p., MARVEL, J., Walzer, T., Trouillet-Assant, S.
10.1101/2025.02.18.638851 — Posted: 2025-02-21
Active vaccine safety surveillance: Experience from a prospective cohort event monitoring study of COVID-19 vaccines in Kenya
Odhiambo, D. B., Akech, D., Karia, B., Kimani, M., Sang, S., Sigilai, A., Voller, S., Mataza, C., Mang'ong'o, D., Jalang'o, R., Mandale, M., Etyang, A. O., Scott, J. A. G., Agweyu, A., Kagucia, E. W.
10.1101/2025.02.18.25322051 — Posted: 2025-02-20
evoSSS: Modeling the Competitive Evolution and Large-scale Transmission Dynamics of SARS-CoV-2 and Emerging Viral Pathogens
Huang, S., Lu, X., Xiao, Z., Zhuang, Y., Wei, X., Fan, Z., Huang, L., Zhao, S., Lynch, M., Yao, H., Zheng, M., Jiang, C.
10.1101/2025.02.15.25322128 — Posted: 2025-02-20
Changed epidemiology of influenza and RSV hospitalizations after the emergence of SARS-CoV-2 in Norway, 2017 - 2024
Boas, H., Seppala, E. M., Veneti, L., Stalcrantz, J., Berild, J. D., Dahl, J., Paulsen, T. H.
10.1101/2025.02.17.25322411 — Posted: 2025-02-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).